PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Roche acquires Irish biotech firm Inflazome

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m).

In addition to the upfront payment, Inflazome is also eligible to receive additional contingent payments, based on the achievement of predetermined milestones.

The start-up biotech was founded back in 2016 by medical researchers Professor Matt Cooper and Professor Luke O’Neill, with a focus on the development of inflammasome inhibitors.

“We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications,” said Matt Cooper, chief executive officer of Inflazome.

With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”

Following the acquisition, Roche gains full rights to Inflazome’s entire portfolio of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche has plans to further develop Inflazome’s products across a wide range of indications with high unmet medical need.

Activated NLRP3 is involved in the production of pro-inflammatory cytokines IL-1? and IL-18, which are believed to be a driving force behind several chronic inflammatory conditions.

The biotech is currently working on the development of drugs targeting inflammasomes associated with Parkinson’s disease, Alzheimer’s disease, asthma, inflammatory bowel disease, arthritis and other chronic inflammatory disease.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026